Broad CRISPR loss shows how not to file a priority claim
Life sciences in-house sources stress the importance of following the EPO’s strict priority claims guidelines after the Board of Appeal invalidated some of the Broad Institute’s CRISPR patents
The EPO’s decision to revoke some of the Broad Institute’s CRISPR-Cas9 patents was expected, and serves as a strict reminder to biotech businesses to file priority claims correctly, say in-house counsel at pharmaceutical and life sciences companies.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.